Marine Leberre

3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

Ghassan K Abou Alfa, Peter Johnson, Jennifer J. Knox et al. · European Journal of Cancer Supplements · 2007 · 56 citations

Medicine, Oncology, Pharmacology +14

Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)

Andrew X. Zhu, Olivier Rosmorduc, Jenny Evans et al. · Annals of Oncology · 2012 · 49 citations · Full text

Medicine, Oncology, Pharmacology +14

LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial

Jordi Bruix, Philippe Merle, Alessandro Granito et al. · Annals of Oncology · 2016 · 39 citations · Full text

Medicine, Oncology, Pharmacology +7

Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE).

Riccardo Lencioni, Jingwen Zou, Marine Leberre et al. · Journal of Clinical Oncology · 2010 · 34 citations

Medicine, Oncology, Pharmacology +13

Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults

J.M. Klossek, R. Siegert, Paul Nikolaidis et al. · The Journal of Laryngology & Otology · 2003 · 26 citations

Medicine, Pharmacology, Pharmacotherapy +13